Mostafa Assarroudi

Mostafa Assarroudi

Auto-generated profile, based on publicly available information

Mostafa Assarroudi

Department of Nursing, Torbat Jam Faculty of Medical Sciences, Torbat Jam, Iran

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2022 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
PDF file
EZElahe Zaremoghadam
Elahe Zaremoghadam
EPEnsiye Pordel
Ensiye Pordel
MAMostafa Assarroudi
Mostafa Assarroudi
SMSaeid Mohammadi
Saeid Mohammadi
ASAli Kalali Sani
Ali Kalali Sani
SASara Abbasian
Sara Abbasian
Introduction: Thyroid status because of the expression of angiotensin-converting enzyme-2 (ACE2), which is a functional receptor for coronavirus disease 2019 (COVID-19) in thyroid glands, maybe affects COVID-19 patients’ outcomes. Objectives: This study aimed to evaluate the correlation of thyroid status with the severity and mortality of COVID-19 patients. Patients and Methods: In a retrospective cohort study conducted on 521 COVID-19 patients, data were collected by a demographic questionnaire and a checklist of patient outcomes (death/recovery) from the hospital information system (HIS) and analyzed by SPSS version 26 and binary logistic regression. Data about thyroid status were collected from clinical documents and laboratory test data. Results: Most patients were male (57.2%) with a mean age of 56.12 ± 17.4 years. Seventy-seven patients had a severe stage of disease, and 55 patients died. Twenty-one patients had hyperthyroidism, and 53 patients had hypothyroidism. Results showed that the correlation between hypothyroidism and hyperthyroidism with severity and mortality risk of COVID-19 patients was insignificant (P > 0.05). Conclusion: In this study, we concluded that, thyroid status is not associated with COVID-19 outcomes such as severity or mortality.

24 June 2024 in Journal of Nephropathology
Verified
Journal Article
Open access
ADAnna Ghorbani Doshantapeh
Anna Ghorbani Doshantapeh
ANAtieh Nouralishahi
Atieh Nouralishahi
ACAnahid Cheraghalian
Anahid Cheraghalian
NANavid Asgari
Navid Asgari
RARazieh Bagheri Shahzadeh Aliakbari
Razieh Bagheri Shahzadeh Aliakbari
SKSeyede Sara Pakdaman Kolour
Seyede Sara Pakdaman Kolour
Introduction: Statins reduce the cancer risk; however, non-Hodgkin lymphoma (NHL) evidence remains controversial. Therefore, we aimed to evaluate the relationship between statin consumption and NHL risk using a systematic review and meta-analysis. Materials and Methods: In this systematic review and meta-analysis, international databases, including Scopus, PubMed, Web of Science, Cochrane, and Google Scholar search engines, were searched without a time limit up to September 21, 2023. Data analysis was performed using STATA 14 software, and the significance level was considered P<0.05. Results: The results of combining 13 studies (9 case-control studies and 4 cohort studies) with a total sample size of 1142 740 subjects showed that statin consumption could reduce NHL risk by 22% (RR: 0.78; 95% CI: 0.69, 0.88). Statin consumption in cohort studies reduced NHL risk by 14% (RR: 0.86; 95% CI: 0.77, 0.95), but in case-control studies, it reduced NHL risk by 26% (RR: 0.74; 95% CI: 0.62, 0.90). Furthermore, statin consumption reduced diffuse large B-cell lymphoma risk by 24% (RR: 0.76; 95% CI: 0.67, 0.87) and marginal zone risk by 26% (RR: 0.74; 95% CI: 0.59, 0.93). However, it did not affect reducing the risk of chronic lymphocytic leukemia/small lymphocytic lymphoma (RR: 0.94; 95% CI: 0.85, 1.05), follicular (RR: 0.96; 95% CI: 0.83, 1.10), plasma cell neoplasms (RR: 0.97; 95% CI: 0.70, 1.33), T cell lymphoma (RR: 0.81; 95% CI: 0.55, 1.19) and B cell lymphoma (RR: 0.94; 95% CI: 0.44, 2.01). Conclusion: Statin consumption significantly reduced the risk of NHL, diffuse large B-cell lymphoma, and marginal zone but did not affect other NHL types. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023469126) and Research Registry (UIN: reviewregistry1732) website.

16 May 2023 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
RMRazieh Mousapour
Razieh Mousapour
MAMostafa Assarroudi
Mostafa Assarroudi
YKYaser Khanchemehr
Yaser Khanchemehr
MMMasoomeh Mehrbarjou
Masoomeh Mehrbarjou
GAGolmis Abdolmohammadi
Golmis Abdolmohammadi
HSHussein Soleimantabar
Hussein Soleimantabar
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is a worldwide challenge; regarding the lack of an effective and efficient drug. It seems that the vaccine is the only modality to save the world from this pandemic. Objectives: This study was conducted to assess the effect of vaccination on preventing pulmonary involvement and the disease severity of COVID-19 patients. Patients and Methods: This descriptive-analytical study was conducted on 247 people with coronavirus disease 2019 infection. Demographic characteristics and vaccination status information were collected. Patients’ lung computed tomography scan findings were scored based on the pulmonary involvement percentage, and then according to this score, they were graded into severe, moderate, mild, and without lung involvement. The association between pulmonary involvement and vaccination status were evaluated by Fisher’s exact test and logistic regression. Results: Most participants were male, with a mean age of 53.74 ± 10.96 years. Most people (42.9%) were partial-vaccinated. Lungs in 53.3% were with lung involvement and in 46.6% were without. The correlation between pulmonary involvement and vaccination was significant (P<0.001). Conclusion: Vaccination is an effective and efficient method in preventing coronavirus disease 2019 severity.

1 January 2023 in Journal of Renal Endocrinology
Verified
Journal Article
Open access
PDF file
NANoorbakhsh Alivand
Noorbakhsh Alivand
HMHanieh Molaee
Hanieh Molaee
MAMostafa Assarroudi
Mostafa Assarroudi
AMAmin Fatehi Moazam
Amin Fatehi Moazam
SDSara Dehghan
Sara Dehghan
SASoleyman Alivand
Soleyman Alivand
Fibroblast growth factor 23 (FGF23) is a hormone that plays a critical role in regulating mineral homeostasis in the body. Specifically, FGF23 acts on the kidneys to decrease the reabsorption of phosphate from the blood and into the urine. This process helps to reduce serum phosphate levels and maintain balance alongside other hormones such as PTH. The primary responsibility of FGF23 is to regulate the balance of phosphate in the body. It does this by acting on the kidney cells to decrease the reabsorption of phosphate from the blood and into the urine. This process allows the body to excrete excess phosphate to maintain normal serum phosphate levels in the blood. In addition to regulating phosphate levels, FGF23 also plays a role in the metabolism of vitamin D. FGF23 can increase the metabolism of vitamin D to an inactive form, reducing the amount of active vitamin D in the body. This reduction in active vitamin D levels leads to decreased intestinal absorption of dietary calcium and phosphate. Abnormal levels of FGF23 in the body have been associated with several health concerns, particularly in patients with chronic kidney disease. High levels of FGF23 have been linked to the development of bone loss, vascular calcification, and cardiovascular disease. Conversely, low levels of FGF23 have been associated with an increased risk of mortality and cardiovascular disease in patients with kidney disease.